RNAi Technology Market to Grow with a CAGR of 10.28% through 2030
Rising advancements in drug discovery and development are
expected to drive the Global RNAi Technology Market growth in the forecast
period, 2026-2030.
According to TechSci Research report, “RNAi
Technology Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2030”, the Global RNAi Technology Market
stood at USD 1.19 billion in 2024 and is anticipated to grow with a CAGR of 10.28%
in the forecast period through 2030. The Global RNAi Technology Market is a thriving and
dynamic industry that encompasses various sectors, from healthcare to
agriculture and research. With its transformative potential in gene regulation
and therapy, RNAi technology is poised to drive innovation and address some of
the most pressing challenges in science and medicine. As research and
development efforts continue to advance, this market is likely to witness
sustained growth and innovation in the coming years. One of the primary drivers fueling the RNAi technology
market is the increasing demand for RNAi-based therapeutics. RNAi offers a
unique approach to target specific genes responsible for various diseases,
including cancer, viral infections, and genetic disorders. This precision
medicine approach holds great promise for developing highly effective and
targeted therapies. Pharmaceutical companies are actively investing in RNAi
research and clinical trials to develop a new generation of drugs. The global
burden of chronic diseases, such as cancer, diabetes, and neurodegenerative
disorders, continues to rise. RNAi technology's ability to selectively silence
disease-associated genes has the potential to revolutionize the treatment of
these conditions. With an aging population and changing lifestyles contributing
to the prevalence of chronic diseases, the demand for innovative therapies that
target the underlying genetic causes is expected to drive the RNAi technology
market's growth.
Efficient and safe delivery of RNAi molecules to
target cells has been a major challenge in the field. However, significant
advancements in delivery systems have been made, enabling the effective
administration of RNAi therapeutics. Lipid nanoparticles, viral vectors, and
nanoparticle-based carriers have shown promise in enhancing the delivery of
RNAi molecules to specific tissues and cells. These innovations have opened up
new avenues for the development of RNAi-based drugs and have contributed to the
market's expansion. The RNAi technology market benefits from a robust ecosystem
of research and development activities. Academic institutions, biotechnology
companies, and research organizations are actively exploring the potential of
RNAi in various applications, including functional genomics, target validation,
and drug discovery. This continuous exploration and innovation contribute to
the growth of the RNAi technology market by expanding its scope and
applications.
RNAi technology has become an indispensable tool in
functional genomics and drug discovery. Researchers are using RNAi to
investigate gene functions, validate drug targets, and identify potential
therapeutic candidates. The ability to selectively silence specific genes has
accelerated the pace of drug development by enabling a more precise
understanding of disease mechanisms and pathways.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global RNAi Technology Market.”
The Global RNAi Technology Market is segmented into Type,
Application, End User, Regional Distribution and Company.
Based on the Application, the Therapeutics segment
emerged as the fastest category in the global market for Global RNAi Technology
Market. Chronic diseases such as
cancer, diabetes, cardiovascular disorders, and neurodegenerative conditions
are on the rise worldwide. RNAi-based therapeutics hold great promise in
treating these diseases by specifically targeting the genetic drivers of these
conditions. RNA interference
(RNAi) technology has made remarkable strides in the development of RNAi-based
therapeutics. The successful FDA approval of drugs like Onpattro® for
hereditary transthyretin amyloidosis demonstrates the clinical potential of
RNAi-based therapies. The global healthcare landscape is increasingly
emphasizing precision medicine, which tailors treatments to individual patients
based on their genetic makeup. RNAi technology aligns perfectly with this
approach, offering precise and targeted therapies for a wide range of diseases.
Moreover, RNAi technology
allows for the development of customized treatments by targeting
disease-associated genes and pathways. This personalization of therapies can
result in more effective treatments with fewer side effects.
Based on the region, The Asia-Pacific region is experiencing the fastest growth in the RNAi Technology Market, driven by increasing investments in biotechnology research, expanding clinical applications, and rising demand for targeted therapeutics. The region benefits from a growing number of biotech startups, government initiatives supporting RNA-based drug development, and collaborations between academic institutions and pharmaceutical companies. Additionally, the rising prevalence of genetic disorders and chronic diseases is fueling the demand for RNAi-based therapies, further propelling market expansion.
Major companies operating in Global RNAi
Technology Market are:
- Alnylam Pharmaceuticals, Inc
- Ionis Pharmaceuticals, Inc.
- Atalanta Therapeutics
- Phio Pharmaceuticals
- Benitec Biopharma
- Novartis AG
- AstraZeneca
- Silence Therapeutics
- Arbutus Biopharma
- Sylentis S.A.
Download
Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Global RNAi
Technology Market is poised for substantial growth in the coming years, driven
by several key factors. Firstly, the increasing prevalence of chronic diseases,
such as cancer, diabetes, and neurodegenerative disorders, is fueling the
demand for precision medicine solutions, making RNAi-based therapies more
attractive. Furthermore, advancements in delivery systems and the ability to
mitigate off-target effects are enhancing the safety and efficacy of RNAi
technology, encouraging its adoption in clinical settings. Additionally, the
convergence of RNAi technology with precision medicine and personalized
therapies aligns with the evolving healthcare paradigm, where treatments are
tailored to individual patient profiles. The expanding role of RNAi in
functional genomics and drug discovery is accelerating research efforts and
identifying novel drug targets. Collaborations, government funding, and
intellectual property management are fostering innovation, while the expansion
of RNAi technology into agriculture for crop protection is creating new market
opportunities.” said Mr. Karan Chechi, Research Director of TechSci Research,
a research-based management consulting firm.
“RNAi Technology Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, Segmented By Type (Micro RNA, Small
interfering RNA, Others), By Application (Treatment Type, Therapeutics, Drug Delivery,
Agriculture, Others), By End User (Research and Academic Laboratories,
Diagnostic Laboratories, Others), By Region and Competition, 2020-2030F”, has evaluated
the future growth potential of Global RNAi Technology Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global RNAi Technology Market.
Contact
TechSci Research LLC
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: sales@techsciresearch.com
Website: www.techsciresearch.com